Non-mercaptalbumin as a potential biomarker of oxidative stress in Parkinson’s and PARK2 disease
Objective: To elucidate the oxidized albumin ratio, which is the redox ratio of human non-mercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in parkinsonism.…Neuroprotective and neuromodulatory properties of Olea purpurea leaf extract in MPTP intoxicated Parkinsonian rat model
Objective: This study aimed to isolate and characterize Olea purpurea leaf extract, and its neuroprotective effect in MPTP induced parkinsonian rat model. Background: Parkinson's disease (PD), also…The relationship between serum uric acid and depression in patients with essential tremor
Objective: To identity a correlation between serum indicators oxidative stress (uric acid, malondialdehyde and ceruloplasmin) and clinical symptoms in patients with ET. Background: Essential tremor…Neuroprotective actions of red propolis extract and formononetin in a rat model of Parkinson’s disease
Objective: To evaluate the effects of the hydroalcoholic extract of red propolis (HERP) and one of its major compounds, formononetin (FN), against the motor symptoms…Quercetin administration abrogates the Parkinson’s disease (PD)-like motor and non-motor symptoms and attenuates the behavioral, neurochemical and biochemical deficits induced by rotenone toxicity in rats
Objective: The present study was carried out to investigate the preventive and therapeutic effects of quercetin (a flavonol) against rotenone-induced neurotoxicity. Background: Rotenone (pesticide) induced…Protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease
Objective: Objective of our study was to evaluate protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease. Background: Parkinson’s disease (PD),…Dietary Vitamin E as a protective factor for Parkinson’s Disease: a clinical and experimental study
Objective: To test if a higher dietary intake of Vitamin E might represent a protective factor in Parkinson’s disease (PD). Background: Effective disease-modifying treatments are…Factors underlying reduced aerobic capacity in Huntington disease
Objective: Examine factors underlying aerobic capacity in prodromal and manifest Huntington disease (HD) and matched controls Background: HD results in motor impairments, weight loss, muscle…Phosphodiesterase inhibitors as a treatment for Friedreich’s ataxia
Objective: To evaluate the effect of phosphodiesterase inhibitors, as potential treatment for Friedreich’s ataxia, in a Drosophila melanogaster model of the disease. Background: Friedreich’s ataxia…Ferroptosis, a recently identified cell death, as a therapeutic target for Parkinson’s disease.
Objective: We aim to determine in a cell model neuroprotective effects of targeting lipoxygenases (LOXs), central players in Ferroptosis, a novel regulated iron-dependent cell death…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 8
- Next Page »
